Company profile: Lentigen Technology
1.1 - Company Overview
Company description
- Provider of gene delivery technologies and CDMO services for cell and gene therapy products, offering lentiviral vector technology for therapeutic, vaccine, and research applications; lentiviral vector design, evaluation, and scalable manufacturing; process development and clinical manufacturing; assay development via automated flow cytometry; and regulatory support from pre-IND to approval.
Products and services
- Lentiviral Vector Optimization and Manufacturing: Architects, evaluates, and produces lentiviral vectors, optimizing plasmid designs and executing scalable manufacturing for therapeutic, vaccine, and research applications
- Clinical Cell Therapy Manufacturing: Constructs, analyzes, and releases cell and gene therapy products for clinical use, leveraging automated technologies and GMP-compliant processes
- CDMO Services: Delivers development and manufacturing services for lentiviral vectors and cell and gene therapy products, supporting programs from pre-clinical through commercial-scale across biotechnology and medicine.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lentigen Technology
Provista Diagnostics
HQ: United States
Website
- Description: Provider of blood-based diagnostic tests focused on oncology, including Videssa Breast Cancer Test combining serum protein biomarkers and tumor-associated autoantibodies for high-accuracy detection in women with abnormal imaging findings. Also offers COVID-19 PCR testing with same-day results from car-based collection, Long COVID panel, FDA-EUA real-time qPCR respiratory tests, UTI PCR testing, and wound infection testing with antibiotic resistance assessment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Provista Diagnostics company profile →
SNIPR Biome
HQ: Denmark
Website
- Description: Provider of CRISPR-based microbial gene therapies that selectively target and eliminate hazardous bacteria without harming beneficial microbes; gut-directed gene therapy via engineered bacteria; CRISPR-Guided Vectors (CGV) for rapid, precise bacterial killing; platforms for in situ therapeutic protein and peptide production; backed by an extensive patent portfolio and research collaborations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SNIPR Biome company profile →
Gentris
HQ: United States
Website
- Description: Provider of global pharmacogenomic testing and biorepository services, helping pharmaceutical companies and clinical research organizations integrate pharmacogenomics into drug development to deliver safer, more effective compounds to market more quickly.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gentris company profile →
Adverum Biotechnologies
HQ: United States
Website
- Description: Provider of gene therapy, developing medicines with therapeutic benefits. Offerings include Ixo-vec, a gene therapy product candidate for wet age-related macular degeneration designed for single administration, and the OPTIC clinical program investigating the safety, efficacy, and long-term outcomes of Ixo-vec in wet AMD patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adverum Biotechnologies company profile →
Bluebee
HQ: The Netherlands
Website
- Description: Provider of a secure global, cloud-based accelerated bio-informatics/genomics platform and high-performance genomics solutions to process, analyze, share and store large volumes of genomics data, enabling research and clinical labs to reduce cost and time-to-diagnose.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bluebee company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lentigen Technology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lentigen Technology
2.2 - Growth funds investing in similar companies to Lentigen Technology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lentigen Technology
4.2 - Public trading comparable groups for Lentigen Technology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →